August 27th 2024
Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.
August 24th 2022
Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
August 17th 2022
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
August 10th 2022
Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.
Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.
August 3rd 2022
Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.
Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.
July 27th 2022
Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.
Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.
July 20th 2022
Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.
Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.
July 13th 2022
A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.
Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.
October 17th 2018
Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma.